231 related articles for article (PubMed ID: 26845565)
1. BS69/ZMYND11 C-Terminal Domains Bind and Inhibit EBNA2.
Harter MR; Liu CD; Shen CL; Gonzalez-Hurtado E; Zhang ZM; Xu M; Martinez E; Peng CW; Song J
PLoS Pathog; 2016 Feb; 12(2):e1005414. PubMed ID: 26845565
[TBL] [Abstract][Full Text] [Related]
2. Increased association between Epstein-Barr virus EBNA2 from type 2 strains and the transcriptional repressor BS69 restricts EBNA2 activity.
Ponnusamy R; Khatri R; Correia PB; Wood CD; Mancini EJ; Farrell PJ; West MJ
PLoS Pathog; 2019 Jul; 15(7):e1007458. PubMed ID: 31283782
[TBL] [Abstract][Full Text] [Related]
3. The conserved Mynd domain of BS69 binds cellular and oncoviral proteins through a common PXLXP motif.
Ansieau S; Leutz A
J Biol Chem; 2002 Feb; 277(7):4906-10. PubMed ID: 11733528
[TBL] [Abstract][Full Text] [Related]
4. The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.
Liu CD; Chen YL; Min YL; Zhao B; Cheng CP; Kang MS; Chiu SJ; Kieff E; Peng CW
PLoS Pathog; 2012; 8(12):e1003084. PubMed ID: 23271972
[TBL] [Abstract][Full Text] [Related]
5. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
[TBL] [Abstract][Full Text] [Related]
6. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
7. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.
Fuentes-Pananá EM; Ling PD
J Virol; 1998 Jan; 72(1):693-700. PubMed ID: 9420275
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
J Virol; 2018 May; 92(9):. PubMed ID: 29467311
[TBL] [Abstract][Full Text] [Related]
10. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
[TBL] [Abstract][Full Text] [Related]
11. EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.
Gordadze AV; Onunwor CW; Peng R; Poston D; Kremmer E; Ling PD
J Virol; 2004 Apr; 78(8):3919-29. PubMed ID: 15047808
[TBL] [Abstract][Full Text] [Related]
12. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.
Su C; Lu F; Soldan SS; Lamontagne RJ; Tang HY; Napoletani G; Farrell PJ; Tempera I; Kossenkov AV; Lieberman PM
PLoS Pathog; 2021 Aug; 17(8):e1009834. PubMed ID: 34352044
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional analysis of the DEAF-1 and BS69 MYND domains.
Kateb F; Perrin H; Tripsianes K; Zou P; Spadaccini R; Bottomley M; Franzmann TM; Buchner J; Ansieau S; Sattler M
PLoS One; 2013; 8(1):e54715. PubMed ID: 23372760
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
[TBL] [Abstract][Full Text] [Related]
15. Binding of the heterogeneous ribonucleoprotein K (hnRNP K) to the Epstein-Barr virus nuclear antigen 2 (EBNA2) enhances viral LMP2A expression.
Gross H; Hennard C; Masouris I; Cassel C; Barth S; Stober-Grässer U; Mamiani A; Moritz B; Ostareck D; Ostareck-Lederer A; Neuenkirchen N; Fischer U; Deng W; Leonhardt H; Noessner E; Kremmer E; Grässer FA
PLoS One; 2012; 7(8):e42106. PubMed ID: 22879910
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
Zhao B; Zou J; Wang H; Johannsen E; Peng CW; Quackenbush J; Mar JC; Morton CC; Freedman ML; Blacklow SC; Aster JC; Bernstein BE; Kieff E
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14902-7. PubMed ID: 21746931
[TBL] [Abstract][Full Text] [Related]
17. The Transcriptional Repressor BS69 is a Conserved Target of the E1A Proteins from Several Human Adenovirus Species.
Zhang A; Tessier TM; Galpin KJC; King CR; Gameiro SF; Anderson WW; Yousef AF; Qin WT; Li SSC; Mymryk JS
Viruses; 2018 Nov; 10(12):. PubMed ID: 30469473
[TBL] [Abstract][Full Text] [Related]
18. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
19. EBF1 binds to EBNA2 and promotes the assembly of EBNA2 chromatin complexes in B cells.
Glaser LV; Rieger S; Thumann S; Beer S; Kuklik-Roos C; Martin DE; Maier KC; Harth-Hertle ML; Grüning B; Backofen R; Krebs S; Blum H; Zimmer R; Erhard F; Kempkes B
PLoS Pathog; 2017 Oct; 13(10):e1006664. PubMed ID: 28968461
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional characterization of a complex between the acidic transactivation domain of EBNA2 and the Tfb1/p62 subunit of TFIIH.
Chabot PR; Raiola L; Lussier-Price M; Morse T; Arseneault G; Archambault J; Omichinski JG
PLoS Pathog; 2014 Mar; 10(3):e1004042. PubMed ID: 24675874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
